SAN FRANCISCO -- Perioperative treatment with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) significantly improved survival compared with standard neoadjuvant chemotherapy in patients with ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results